CellPress is showcasing a collection of CTD² Network’s articles which will help develop precision therapeutics in cancer. Register for the Cell-NCI Symposium: Beyond Cancer Genomics Toward Precision Oncology taking place from October 4-6, 2021.
Publications
599 Publications Available
March 01, 2020
Clin Cancer Res.
March 01, 2020
Nature Biotechnology
CTD2 scientists at UCSF used CRISPR interference approach to study gene-specific expression–phenotype relationships and expression level-dependent cell responses at single-cell resolution. This technique could be used in drug development, functional genomics, and identification of suppressor.
February 21, 2020
Nat Commun.
Scientists performed WGS, RNA and T-cell receptor sequencing, immunohistochemistry and reverse phase protein array profiling on pediatric and adult samples. Study indicated that genomic complexity causes immunosuppressive phenotype and provides opportunities for developing novel treatments.
February 20, 2020
Conversations on mutism: risk stratification for cerebellar mutism based on medulloblastoma subtype.
Neuro-Oncology
Risk stratification of medulloblastoma subtype could minimize the burden of cerebellar mutism syndrome burden on pediatric patients with posterior fossa tumors, a type of brain tumor located in or near the bottom of the skull.
February 14, 2020
Clinical Cancer Research
Stanford University used single-cell genomics to characterize heterogenous cell types and states in tumor microenvironment revealing changes in transcriptional states, regulatory networks, and intercellular communication between matched gastric tumor and normal tissue from same patients.
February 14, 2020
Clinical Cancer Research
Report on challenges and opportunities associated with translating basic science discoveries in glioblastoma discussed during the neuro-oncology community meeting in April 2019.
February 06, 2020
Blood
Human pluripotent stem cells-derived natural killer cells have improved antibody-dependent cellular cytotoxicity and could be used to treat refractory malignancies.
February 05, 2020
Nature Communications
Scientists analyzed whole genomes of over 2500 tumors from 27 different cancer types and identify new components of cancer pathways that are altered by coding and non-coding mutations.
February 03, 2020
Gynecologic Oncology Reports
Phase II clinical trial with single-agent Akt inhibitor, MK2206, in recurrent platinum-resistant high-grade serous ovarian cancers with molecular aletarions in PI3K/AKT pathway is not effictive.
February 01, 2020
Nature
CTD2 scientists developed a high-throughput in vivo complementation screening platform that enabled discovery of driver mutations of PIK3CA in glioblastoma. These studies highlight that variant function is context specific.
Pages
.